UNCY Unicycive Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1766140 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-8.4%
TTM EPS YoY53.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-80.4%
ROA-60.1%
ROIC (approx.)-1,005.6%
Asset turnover—
Leverage & solvency
Liabilities / assets24.8%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $675,000 | $951,000 | — |
| R&D expense | $9.12M | $20.01M | $12.90M | $12.44M | $6.08M |
| SG&A expense | $20.40M | $12.10M | $8.55M | $6.57M | $245,000 |
| Operating income | -$29.52M | -$32.12M | -$20.77M | -$18.05M | -$8.98M |
| Interest expense | $71,000 | $71,000 | $82,000 | $6,000 | $628,000 |
| Net income | -$26.55M | -$36.73M | -$30.54M | -$18.06M | -$10.02M |
| EBITDA | -$29.48M | -$32.09M | -$20.77M | -$18.05M | -$8.51M |
| EPS (basic) | -1.67 | -5.65 | -1.28 | -1.20 | -0.86 |
| EPS (diluted) | -1.67 | -5.65 | -1.28 | -1.20 | -0.86 |
| Weighted avg. shares (diluted) | 15.89M | 6.70M | 24.54M | 15.06M | 11.68M |
| Balance sheet | |||||
| Cash & equivalents | $29.20M | $26.14M | $9.70M | $455,000 | $16.58M |
| Short-term investments | $12.07M | — | — | — | — |
| Inventory | — | — | — | $2.19M | $1.83M |
| Current assets | $48.96M | $30.95M | $13.40M | $2.64M | $18.41M |
| PP&E, net | $66,000 | $75,000 | $26,000 | $22,000 | $28,000 |
| Total assets | $49.13M | $31.67M | $14.19M | $2.82M | $18.74M |
| Current liabilities | $18.94M | $24.12M | $17.53M | $3.28M | $2.10M |
| Total liabilities | $18.94M | $24.24M | $18.00M | $3.28M | $2.26M |
| Shareholders' equity | $30.20M | $7.43M | -$3.81M | -$466,000 | $16.48M |
| Shares outstanding | 22.11M | 11.38M | 34.76M | 15.23M | 15.00M |
| Cash flow statement | |||||
| Operating cash flow | -$31.32M | -$28.57M | -$18.28M | -$15.65M | -$5.77M |
| Capital expenditure | $24,000 | $72,000 | $12,000 | $2,000 | $29,000 |
| Free cash flow | -$31.34M | -$28.65M | -$18.30M | -$15.65M | -$5.80M |
| Investing cash flow | -$12.10M | -$72,000 | -$12,000 | -$2,000 | -$29,000 |
| Financing cash flow | $46.47M | $45.09M | $27.54M | -$471,000 | $22.38M |
| Depreciation & amortization | $34,000 | $22,000 | $9,000 | $7,000 | $468,000 |
| Stock-based compensation | $2.64M | $2.35M | $1.77M | $1.05M | $966,000 |
| Dividends paid | — | $1.09M | $900,000 | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.